Correlation Between VistaGen Therapeutics and Standard Biotools

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both VistaGen Therapeutics and Standard Biotools at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining VistaGen Therapeutics and Standard Biotools into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between VistaGen Therapeutics and Standard Biotools, you can compare the effects of market volatilities on VistaGen Therapeutics and Standard Biotools and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in VistaGen Therapeutics with a short position of Standard Biotools. Check out your portfolio center. Please also check ongoing floating volatility patterns of VistaGen Therapeutics and Standard Biotools.

Diversification Opportunities for VistaGen Therapeutics and Standard Biotools

0.45
  Correlation Coefficient

Very weak diversification

The 3 months correlation between VistaGen and Standard is 0.45. Overlapping area represents the amount of risk that can be diversified away by holding VistaGen Therapeutics and Standard Biotools in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Standard Biotools and VistaGen Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on VistaGen Therapeutics are associated (or correlated) with Standard Biotools. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Standard Biotools has no effect on the direction of VistaGen Therapeutics i.e., VistaGen Therapeutics and Standard Biotools go up and down completely randomly.

Pair Corralation between VistaGen Therapeutics and Standard Biotools

Given the investment horizon of 90 days VistaGen Therapeutics is expected to generate 0.6 times more return on investment than Standard Biotools. However, VistaGen Therapeutics is 1.66 times less risky than Standard Biotools. It trades about -0.02 of its potential returns per unit of risk. Standard Biotools is currently generating about -0.1 per unit of risk. If you would invest  281.00  in VistaGen Therapeutics on December 30, 2024 and sell it today you would lose (22.00) from holding VistaGen Therapeutics or give up 7.83% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

VistaGen Therapeutics  vs.  Standard Biotools

 Performance 
       Timeline  
VistaGen Therapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days VistaGen Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, VistaGen Therapeutics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.
Standard Biotools 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Standard Biotools has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

VistaGen Therapeutics and Standard Biotools Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with VistaGen Therapeutics and Standard Biotools

The main advantage of trading using opposite VistaGen Therapeutics and Standard Biotools positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if VistaGen Therapeutics position performs unexpectedly, Standard Biotools can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Standard Biotools will offset losses from the drop in Standard Biotools' long position.
The idea behind VistaGen Therapeutics and Standard Biotools pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Other Complementary Tools

Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
CEOs Directory
Screen CEOs from public companies around the world